Heyholder
‹ Activism Filings

UNION KOREA PHARM CO.,Ltd Q3 revenue KRW 7.8 billion, operating loss KRW 3.5 billion

UNION KOREA PHARM CO.,Ltd· Periodic Report

AI summary · Not investment advice

Korea Union Pharm sold KRW 7.8 billion in Q3 and lost KRW 3.5 billion from its main business, versus a KRW 9.9 billion loss a year earlier.

Operating profit · 3 months

KRW -3.5 billion

Key facts

Revenue (3 months)
KRW 7.8 billion
Net income (3 months)
KRW -7.0 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 7.1 billion
Revenue (year to date)
KRW 19.6 billion
Operating profit (prior-year 3 months)
KRW -9.9 billionOperating loss
Operating profit (year to date)
KRW -6.3 billionOperating loss
Net income (prior-year 3 months)
KRW -11.0 billionNet loss
Net income (year to date)
KRW -7.1 billionNet loss

Commentary

AI commentary · Not investment advice

What happened

Korea United Pharm reported its 3rd-quarter results on a consolidated basis, covering July to September.

In the company's terms

Sales for the 3 months were KRW 7.77 billion. That is 9.0% more than the same period a year earlier and 30.7% more than the previous quarter. Cumulative sales for the year so far are KRW 19.61 billion.

What changes for shareholders

Operating profit (profit from the core business) was a loss of KRW 3.50 billion for the 3 months. A year earlier, the same period had a loss of KRW 9.91 billion. The cumulative operating loss for the year is KRW 6.32 billion.

Net income (the final profit after taxes and other items) was a loss of KRW 6.98 billion for the 3 months. The previous quarter was profitable, so this marks a swing to a loss. A year earlier, the net loss was KRW 11.02 billion. The cumulative net loss for the year is KRW 7.12 billion.

Comments

No comments yet

Comments from shareholders will appear here.